Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTNS vs Solifenacin for Overactive Bladder
NCT06024005Completed
- Sponsor
- Ege University
- Start
- Apr 2023
- Primary completion
- May 2023
- Countries
- 1
01
Overview
Randomised, open-label trial (2 arms), sponsored by Ege University. Primary endpoints: Number of Total Daily Incontinence Episodes at 6 weeks and Evaluation of Quality of Life at 6 weeks. Started Apr 2023; status: completed.
Beyond the preview
Go deeper on NCT06024005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06024005.